Human epidermal growth factor receptor 2 targeted therapy in endometrial cancer: Clinical and pathological perspectives

doi:10.5306/wjco.v12.i10.868

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 10

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (11123)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

623

WORD

290

HTML

5519

Figures (1-2)

512

Tables (1-2)

657

Sum=7601

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

427

Download

1237

Sum=1664

Publishing Process of This Article

Item

Count

Browse

567

Download

1282

Sum=1849

Oct 24, 2021 (publication date) through Feb 15, 2026

Times Cited of This Article

Times Cited (17)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Minireviews

World J Clin Oncol. Oct 24, 2021; 12(10): 868-881
Published online Oct 24, 2021. doi: 10.5306/wjco.v12.i10.868

Human epidermal growth factor receptor 2 targeted therapy in endometrial cancer: Clinical and pathological perspectives

Ayumi Saito, Hiroshi Yoshida, Tadaaki Nishikawa, Kan Yonemori

Ayumi Saito, Tadaaki Nishikawa, Kan Yonemori, Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo 1040045, Japan

Hiroshi Yoshida, Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo 1040045, Japan

Author contributions: Saito A, Yoshida H, Nishikawa T, and Yonemori K contributed equally to this work.

Conflict-of-interest statement: All the authors have no conflict of interest to declare.

Corresponding author: Hiroshi Yoshida, MD, PhD, Staff Physician, Department of Diagnostic Pathology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo 1040045, Japan. hiroyosh@ncc.go.jp

Received: February 26, 2021
Peer-review started: February 26, 2021
First decision: June 7, 2021
Revised: June 14, 2021
Accepted: September 2, 2021
Article in press: September 2, 2021
Published online: October 24, 2021
Processing time: 237 Days and 22.9 Hours

Core Tip

Core Tip: Endometrial cancer is the most common gynecological cancer in developed countries, and its incidence has increased. A significant proportion of endometrial cancer, which mainly comprises high-grade or type II endometrial cancer, including serous carcinoma and carcinosarcoma, shows a dismal prognosis. Recent molecular analyses revealed human epidermal growth factor receptor 2 (HER2) overexpression/ gene amplification in 20%-40% of patients with type II endometrial cancer. Notably, HER2 targeted therapy for type II endometrial cancer has been dramatically developed. We review the recent findings on endometrial cancer, current treatment, optimized HER2 testing, key clinical trials on HER2 targeted therapy, and future directions in these aggressive endometrial cancers.